SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors
Abstract
Convalescent plasma therapy is a leading treatment for conferring temporary immunity to COVID-19–susceptible individuals or for use as post-exposure prophylaxis. However, not all recovered patients develop adequate antibody titers for donation and the relationship between avidity and neutralizing titers is currently not well understood.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 10, 2020
- Source ID
- 10.1093/infdis/jiaa581
Entities
People
- Aaron Tobian
- Andrew D. Redd
- Andrew Pekosz
- Arturo Casadevall
- Charles S. Kirby
- David P Sullivan
- Eshan U Patel
- Ethan Klock
- Evan M Bloch
- Haley A. Schmidt
- Imani Burgess
- Jernelle Miller
- Kirsten Littlefield
- Morgan Keruly
- Oliver Laeyendecker
- Owen R. Baker
- Patrizio Caturegli
- Reinaldo E. Fernandez
- Ruchee Shrestha
- Sarah E. Benner
- Shmuel Shoham
- Tania S. Bonny
- Thomas C. Quinn
- William Clarke
- Yolanda Eby
Organizations
- Bloomberg Philanthropies
- Cancer Genomics Centre
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- Johns Hopkins Bloomberg School of Public Health
- Johns Hopkins School of Medicine
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health